MedTrace Logo

This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK

NCT05747001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 319

Last updated 2024-02-09

No results posted yet for this study

Summary

Cenobamate is a newly-FDA and EMA approved drug used to treat -focal-onset seizures in adult patients.

The aim of the current study is to analyse retrospectively the overall effectiveness and tolerability of cenobamate from real-world data collected in patients who partecipated in the Early Access Program (EAP) and were treated with cenobamate as adjunctive ASM.

Conditions

Sponsors & Collaborators

  • Hippocrates Research

    collaborator OTHER

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Principal Investigators

  • Sylvain Rheims · Hôpital Neurologique Pierre Wertheimer - Hospices Civils de Lyon

  • Rhys Thoma · The Newcastle upon Tyne Hospitals NHS Trust Victoria Road, Newcastle, NE1 4LP

  • Felix Rosenow · Epilepsy Center Frankfurt Rhine-Main Neurocenter Schleusenweg 2 - 16 (Haus 95) 60528 Frankfurt am Main

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05747001 on ClinicalTrials.gov